(1R,2R,3S)-3[(R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy]-2-(4-fluorophenyl)cyclopentane-1-carboxylic acid methyl ester | 190271-63-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (1R,2R,3S)-3[(R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy]-2-(4-fluorophenyl)cyclopentane-1-carboxylic acid methyl ester
• 英文别名: methyl ((1R),(2R),(3S))-3-((1R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-2-(4-fluorophenyl)cyclopentanecarboxylate；methyl (1R,2R,3S)-3-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-2-(4-fluorophenyl)cyclopentane-1-carboxylate
• CAS: 190271-63-7
• 化学式: C₂₃H₂₁F₇O₃
• 分子量: 478.407
• InChiKey: PDMCXDJSVZAMRI-AFLPVOFRSA-N

物化性质

• 沸点：
  408.1±45.0 °C(Predicted)
• 密度：
  1.34±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  33
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  (1R,2R,3S)-3[(R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy]-2-(4-fluorophenyl)cyclopentane-1-carboxylic acid methyl ester 在 sodium hydroxide 作用下， 以 甲醇 为溶剂， 以98%的产率得到((1R),(2R),(3S))-3-((1R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-2-(4-fluorophenyl)cyclopentane-carboxylic acid
  参考文献：
  名称：

  Cyclopentane-based human NK1 antagonists. Part 2: Development of potent, orally active, water-soluble derivatives

  摘要：

  The synthesis and optimization of a cyclopentane-based hNK1 antagonist scaffold 3, having four chiral centers, will be discussed in the context of its enhanced water-solubility properties relative to the marketed anti-emetic hNK1 antagonist EMEND (R) (Aprepitant). Sub-nanomolar hNK1 binding was achieved and oral activity comparable to Aprepitant in two in vivo models will be described. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.06.044
• 作为产物：
  描述：

  1-氯-4-氟苯 在 palladium diacetate 、 tetrafluoroboric acid 、 5% palladium over charcoal 盐酸 、 potassium phosphate 、 disodium hydrogenphosphate 、 (R)-methyl oxazaborolidine 、 dimethyl sulfide borane 、 硫酸 、 2-(二叔丁基膦)联苯 作用下， 以 四氢呋喃 、 正庚烷 、 二氯甲烷 、 异丁酰胺 、 水 、 甲苯 、 乙腈 为溶剂， -48.0~100.0 ℃ 、68.95 kPa 条件下， 反应 61.75h， 生成 (1R,2R,3S)-3[(R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy]-2-(4-fluorophenyl)cyclopentane-1-carboxylic acid methyl ester
  参考文献：
  名称：

  WO2007/146224

  摘要：

  公开号：

文献信息

• Lactam tachykinin receptor antagonists
  申请人：Finke E. Paul

  公开号：US20050282886A1

  公开（公告）日：2005-12-22

  The present invention is directed to certain lactam compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including emesis, urinary incontinence, depression, and anxiety.

  本发明涉及某些内酰胺化合物，其可用作神经激肽-1（NK-1）受体拮抗剂，以及缓激肽和特别是P物质的抑制剂。该发明还涉及包含这些化合物作为活性成分的药物配方，以及在治疗某些疾病，包括呕吐、尿失禁、抑郁症和焦虑症中使用这些化合物及其配方。
• Combination Therapy for the Treatment of Urinary Frequency, Urinary Urgency and Urinary Incontinence
  申请人：Gottesdiener Keith M.

  公开号：US20090270406A1

  公开（公告）日：2009-10-29

  This invention concerns compositions for the treatment of urinary frequency, urinary urgency and urinary incontinence comprising (R)-N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4-(4-tri-fluoromethylphenyl)thiazol-2-yl]benzenesulfonamide and pharmaceutically acceptable salts thereof. In another aspect, this invention concerns combination therapy for urinary frequency, urinary urgency and urinary incontinence wherein one of the active agents is (R)-N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4-(4-tri-fluoromethylphenyl)thiazol-2-yl]benzenesulfonamide and pharmaceutically acceptable salts thereof.

  这项发明涉及用于治疗尿频、尿急和尿失禁的组合物，包括(R)-N-[4-[2-[[2-羟基-2-(吡啶-3-基)乙基]氨基]乙基]苯基]-4-[4-(4-三氟甲基苯基)噻唑-2-基]苯磺酰胺及其药学上可接受的盐。另一方面，这项发明涉及用于尿频、尿急和尿失禁的联合疗法，其中一种活性药物是(R)-N-[4-[2-[[2-羟基-2-(吡啶-3-基)乙基]氨基]乙基]苯基]-4-[4-(4-三氟甲基苯基)噻唑-2-基]苯磺酰胺及其药学上可接受的盐。
• Zwitterionic tachykinin receptor antagonists
  申请人：——

  公开号：US20020042431A1

  公开（公告）日：2002-04-11

  The present invention is directed to certain novel compounds represented by structural formula I: 1 or a pharmaceutically acceptable salt thereof, wherein R 3 , R 5 , R 6 , R 7 , R 8 , R 11 , R 12 R 13 , Q, W, X, Y and Z are defined herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are tachykinin receptor antagonists and are useful in the treatment of psychiatric disorders including depression and anxiety.

  本发明涉及由结构式I：1所代表的某些新化合物或其药用可接受的盐，其中R3、R5、R6、R7、R8、R11、R12、R13、Q、W、X、Y和Z在此定义。该发明还涉及含有这些新化合物作为活性成分的药物配方，以及该新化合物及其配方在治疗某些疾病中的用途。本发明的化合物是催吐肽受体拮抗剂，可用于治疗包括抑郁症和焦虑症在内的精神障碍。
• Stereoselective Preparation of a Cyclopentane-Based NK1 Receptor Antagonist Bearing an Unsymmetrically Substituted Sec−Sec Ether
  作者：Jeffrey T. Kuethe、Jean-Francois Marcoux、Audrey Wong、Jimmy Wu、Michael C. Hillier、Peter G. Dormer、Ian W. Davies、David L. Hughes

  DOI：10.1021/jo061268x

  日期：2006.9.1

  A highly efficient synthesis of the potent and selective NK-1 receptor antagonist 1 is described. The key transformation involved the etherification reaction between cyclopentanol 12 and chiral imidate 30 which was catalyzed by HBF4 to initially give ether 14 as a 17:1 mixture of diastereomers and in 75% combined yield. The diastereoselectivity was upgraded to 109:1 by crystallization of the triethylamine solvate 44 which was isolated in 54% yield from 12. Mechanistic studies confirmed that the etherification reaction proceeds through an unprecedented S(N)2 reaction pathway under typical S(N)1 reaction conditions.
• WO2008/21029
  申请人：——

  公开号：——

  公开（公告）日：——